New Risk • Jun 11
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 27% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2024 fiscal period end). Share price has been highly volatile over the past 3 months (22% average weekly change). Market cap is less than US$10m (kr56.1m market cap, or US$5.89m). Minor Risk Shareholders have been diluted in the past year (27% increase in shares outstanding). Ankündigung • May 26
2cureX AB (publ), Annual General Meeting, Jun 25, 2026 2cureX AB (publ), Annual General Meeting, Jun 25, 2026, at 10:00 W. Europe Standard Time. Location: premises of forvis mazars, nordenskioldsgatan 11a, se-211 19 malmo, sweden, malmo Sweden New Risk • Dec 30
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2024 fiscal period end). Share price has been highly volatile over the past 3 months (14% average weekly change). Shareholders have been substantially diluted in the past year (43% increase in shares outstanding). Market cap is less than US$10m (kr12.9m market cap, or US$1.40m). New Risk • Aug 24
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended June 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2024 fiscal period end). Share price has been highly volatile over the past 3 months (24% average weekly change). Revenue has declined by 50% over the past year. Shareholders have been substantially diluted in the past year (43% increase in shares outstanding). Revenue is less than US$1m (kr2.0m revenue, or US$208k). Market cap is less than US$10m (kr77.3m market cap, or US$8.14m). Ankündigung • Aug 22
2cureX AB (publ) (OM:2CUREX) acquired Cellphenomics GmbH for €44 million. 2cureX AB (publ) (OM:2CUREX) acquired Cellphenomics GmbH for €44 million in the first half of 2025. A cash consideration of €44 million will be paid by 2cureX AB (publ). As part of consideration, €44 million is paid towards common equity of Cellphenomics GmbH.
2cureX AB (publ) (OM:2CUREX) completed the acquisition of Cellphenomics GmbH for €44 million in the first half of 2025. Ankündigung • Apr 14
2cureX AB (publ), Annual General Meeting, Jun 26, 2025 2cureX AB (publ), Annual General Meeting, Jun 26, 2025, at 15:00 W. Europe Standard Time. Location: at the offices of forvis mazars, located at nordenskioldsgatan 11a, 211 19, malmo Sweden New Risk • Mar 10
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr23m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 34% per year over the past 5 years. Shareholders have been substantially diluted in the past year (43% increase in shares outstanding). Revenue is less than US$1m (kr2.0m revenue, or US$196k). Market cap is less than US$10m (kr10.1m market cap, or US$1.00m). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Ankündigung • Feb 27
2cureX AB (publ) to Report Second Half, 2025 Results on Feb 26, 2026 2cureX AB (publ) announced that they will report second half, 2025 results on Feb 26, 2026 New Risk • Feb 25
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 43% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr23m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 34% per year over the past 5 years. Shareholders have been substantially diluted in the past year (43% increase in shares outstanding). Revenue is less than US$1m (kr2.0m revenue, or US$186k). Market cap is less than US$10m (kr10.0m market cap, or US$946.7k). Ankündigung • Sep 25
2cureX AB (publ) Approves the Election of New Board Members At the Extraordinary General Meeting of 2cureX AB (publ) on 24 September 2024, it was decided to elect Nathaniel Hutley and Dan Honeywell as new board members. The Board of Directors hereafter consists of Tonny Bülow-Nielsen, Grith Hagel, Ole Thastrup, Nathaniel Hutley and Dan Honeywell. Nathaniel Hutley and Dan Honeywell will be strong additions to the Board of Directors with international expertise in building global companies focussing on direct to customer business models. Reported Earnings • Aug 23
First half 2024 earnings released: kr0.54 loss per share (vs kr0.89 loss in 1H 2023) First half 2024 results: kr0.54 loss per share (improved from kr0.89 loss in 1H 2023). Net loss: kr9.56m (loss narrowed 39% from 1H 2023). Ankündigung • Jun 19
2cureX AB (publ) Announces CEO Changes 2cureX AB (publ) announced the appointment of its Founder, Ole Thastrup, as the new CEO. Additionally, the company extend its gratitude to its CFO Kenneth G. Johansen for taking the responsibility as Acting CEO in an interim period. Ankündigung • May 09
2cureX AB (publ) to Report Q4, 2024 Results on Feb 20, 2025 2cureX AB (publ) announced that they will report Q4, 2024 results on Feb 20, 2025 Board Change • Mar 05
No independent directors There are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. No experienced directors. 1 highly experienced director. No independent directors (3 non-independent directors). Co-Founder & Vice Chairman Ole Thastrup is the most experienced director on the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors. Ankündigung • Mar 01
2curex AB (publ) Elects Grith Hagel as a New Board Member 2cureX AB (publ) decided to elect Grith Hagel as a new board member. This election a part of a strategic initiative as 2cureX refines its strategy to facilitate the implementation of IndiTreat® testing across individual hospitals. Such a move towards decentralization necessitates an enhancement of the company's expertise in technical and regulatory areas. Grith Hagel is poised to significantly contribute to the integration and adoption of the IndiTreat® platform within cancer hospitals due to her background and expertise. The Board of Directors hereafter consists of Tonny Bülow-Nielsen, Grith Hagel and Ole Thastrup. Reported Earnings • Feb 25
Full year 2023 earnings released: kr1.75 loss per share (vs kr1.69 loss in FY 2022) Full year 2023 results: kr1.75 loss per share (further deteriorated from kr1.69 loss in FY 2022). Net loss: kr30.8m (loss widened 3.5% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has fallen by 62% per year, which means it is performing significantly worse than earnings. Ankündigung • Jan 10
2cureX AB (publ), Annual General Meeting, May 23, 2024 2cureX AB (publ), Annual General Meeting, May 23, 2024. Ankündigung • Dec 06
2cureX AB (publ) Receives Ethical Approval for HIPEC Clinical Trial 2cureX AB (publ) announced the approval from the Ethical Committee at Fundacion Jimenez Diaz in Madrid to start a clinical trial using IndiTreat? in Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in metastatic colorectal cancer patients. An IndiTreat®? test for this innovative treatment approach will bring additional value to 2cureX's ZENITH project for enabling in-house IndiTreat®? testing at hospital sites. Understanding HIPEC. HIPEC (short for hyperthermic intraperitoneal chemotherapy) is an advanced treatment procedure designed to address cancer metastases in the abdomen. HIPEC procedures comprise the rinsing of the abdominal cavity with heated chemotherapy solutions after surgery. This targeted approach allows for higher local concentrations of chemotherapy with the intention to maximize effectiveness while minimizing systemic side effects. This treatment is primarily offered to patients with cancers originating in the abdominal area, including colorectal cancer, gastric cancer, ovarian cancer, and mesothelioma. HIPEC approaches have shown promising results in increasing survival rates and improving the quality of life for patients with these challenging diagnoses. In this prospective trial, 2cureX's IndiTreat®? tests will identify the cytotoxic drug that has the most promising efficacy profile on an individual HIPEC patient's tumor. Reported Earnings • Nov 24
Third quarter 2023 earnings released: kr0.58 loss per share (vs kr0.47 loss in 3Q 2022) Third quarter 2023 results: kr0.58 loss per share (further deteriorated from kr0.47 loss in 3Q 2022). Net loss: kr10.2m (loss widened 22% from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings. Ankündigung • Nov 15
2Curex AB (Publ) Appoints Tonni Bülow-Nielsen as Board Member and Chairman At the Extraordinary General Meeting of 2cureX AB (publ), 14 November 2023, the Extraordinary general meeting appointed Tonni Bülow-Nielsen as new board members. It was further decided to appoint Tonni Bülow-Nielsen as new Chairman. New Risk • Oct 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr30m free cash flow). Earnings have declined by 39% per year over the past 5 years. Revenue is less than US$1m (kr3.9m revenue, or US$356k). Market cap is less than US$10m (kr59.0m market cap, or US$5.33m). Minor Risk Share price has been volatile over the past 3 months (8.5% average weekly change). Ankündigung • Aug 31
2curex Launches Its First Two IndiTreat® Products Ce-Marked Under the New Ivd Regulation 2cureX announced the launch of two IVD products – IndiTreat® Specimen Collection Kit and IndiTreat® Shipping Container – that have become the first to be CE-marked under the new IVD-R by the company. The IndiTreat® Specimen Collection Kit is a replacement of the previous IndiTreat® Specimen Collection Set, while the IndiTreat® Shipping Container is a new device to ensure optimal conditions during transportation of patient samples from hospitals to the 2cureX testing facilities. The IndiTreat® test is performed on patient-derived 3D tumoroids that are biological replicas of the patient’s original tumor. To grow these 3D tumoroids, it is essential that the biopsy taken from the patient reaches the 2cureX testing facilities in optimal conditions. The IndiTreat® Specimen Collection Kit contains a specialized ready-to-use, single-use buffer capable of supporting the viability of specimen samples during transportation, as well as a temperature logging device to monitor the temperature that the specimen has been exposed to during shipment. The IndiTreat® Shipping Container is a specialized single-use shipping container capable of supporting specimens with optimal shipping conditions by providing stable temperatures within 2-8°C in the sealed payload compartment for at least 48 hours. The two new products will start to be commercialized immediately throughout the 20 countries where 2cureX has commercial operations, directly or through its network of distribution partnerships. Today’s news are in line with launching plans for 2023, and will not affect revenue expectations for the year. New Risk • Aug 25
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr30m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr30m free cash flow). Earnings have declined by 39% per year over the past 5 years. Revenue is less than US$1m (kr3.9m revenue, or US$355k). Market cap is less than US$10m (kr69.2m market cap, or US$6.25m). Reported Earnings • May 26
First quarter 2023 earnings released: kr0.43 loss per share (vs kr0.45 loss in 1Q 2022) First quarter 2023 results: kr0.43 loss per share (improved from kr0.45 loss in 1Q 2022). Net loss: kr7.58m (loss narrowed 4.1% from 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has only fallen by 24% per year, which means it has not declined as severely as earnings. Recent Insider Transactions • May 02
Chief Executive Officer recently bought kr136k worth of stock On the 24th of April, Fernando Andreu bought around 19k shares on-market at roughly kr7.15 per share. This transaction increased Fernando's direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Fernando has been a buyer over the last 12 months, purchasing a net total of kr219k worth in shares. Recent Insider Transactions • Apr 27
Chief Executive Officer recently bought kr136k worth of stock On the 24th of April, Fernando Andreu bought around 19k shares on-market at roughly kr7.15 per share. This transaction increased Fernando's direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Fernando has been a buyer over the last 12 months, purchasing a net total of kr219k worth in shares. Reported Earnings • Apr 24
Full year 2022 earnings released: kr1.69 loss per share (vs kr1.15 loss in FY 2021) Full year 2022 results: kr1.69 loss per share (further deteriorated from kr1.15 loss in FY 2021). Net loss: kr29.8m (loss widened 57% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings. Reported Earnings • Feb 24
Full year 2022 earnings released: kr1.69 loss per share (vs kr1.15 loss in FY 2021) Full year 2022 results: kr1.69 loss per share (further deteriorated from kr1.15 loss in FY 2021). Net loss: kr29.8m (loss widened 57% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings. Ankündigung • Feb 11
2cureX AB (publ) Appoints Michel Klimkeit to Board of Director 2cureX AB (publ) at its extraordinary general meeting resolved the appointment of Michel Klimkeit as member of Board of Director. Reported Earnings • Nov 25
Third quarter 2022 earnings released: kr0.47 loss per share (vs kr0.31 loss in 3Q 2021) Third quarter 2022 results: kr0.47 loss per share (further deteriorated from kr0.31 loss in 3Q 2021). Net loss: kr8.35m (loss widened 54% from 3Q 2021). Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings. Board Change • Nov 16
High number of new and inexperienced directors There are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 3 experienced directors. 1 highly experienced director. Co-Founder, Deputy CEO, CSO & Director Ole Thastrup is the most experienced director on the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Recent Insider Transactions • Jun 07
Chief Executive Officer recently bought kr84k worth of stock On the 2nd of June, Fernando Andreu bought around 7k shares on-market at roughly kr12.39 per share. This was the largest purchase by an insider in the last 3 months. This was Fernando's only on-market trade for the last 12 months. Board Change • Apr 27
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 3 experienced directors. 1 highly experienced director. Co-Founder, Deputy CEO, Member of Executive Board, CSO & Director Ole Thastrup is the most experienced director on the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Board Change • Sep 20
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 4 experienced directors. 1 highly experienced director. Co-Founder, Deputy CEO, Member of Executive Board, CSO & Director Ole Thastrup is the most experienced director on the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Board Change • Sep 14
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 4 experienced directors. 1 highly experienced director. Co-Founder, Deputy CEO, Member of Executive Board, CSO & Director Ole Thastrup is the most experienced director on the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Board Change • Sep 13
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 4 experienced directors. 1 highly experienced director. Co-Founder, Deputy CEO, Member of Executive Board, CSO & Director Ole Thastrup is the most experienced director on the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Board Change • Sep 11
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 4 experienced directors. 1 highly experienced director. Co-Founder, Deputy CEO, Member of Executive Board, CSO & Director Ole Thastrup is the most experienced director on the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Board Change • Sep 09
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 4 experienced directors. 1 highly experienced director. Co-Founder, Deputy CEO, Member of Executive Board, CSO & Director Ole Thastrup is the most experienced director on the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Board Change • Sep 01
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 4 experienced directors. 1 highly experienced director. Co-Founder, Deputy CEO, Member of Executive Board, CSO & Director Ole Thastrup is the most experienced director on the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Board Change • Aug 21
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 4 experienced directors. 1 highly experienced director. Co-Founder, Deputy CEO, Member of Executive Board, CSO & Director Ole Thastrup is the most experienced director on the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Recent Insider Transactions Derivative • Apr 29
Co-Founder exercised options to buy kr7.6m worth of stock. On the 26th of April, Ole Thastrup exercised options to buy 378k shares at a strike price of around kr13.22, costing a total of kr5.0m. This transaction amounted to 10.0% of their direct individual holding at the time of the trade. Since June 2020, Ole has owned 3.78m shares directly. Company insiders have collectively bought kr5.1m more than they sold, via options and on-market transactions, in the last 12 months. Is New 90 Day High Low • Feb 05
New 90-day high: kr22.60 The company is up 54% from its price of kr14.70 on 06 November 2020. The Swedish market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 16% over the same period. Executive Departure • Feb 03
Chief Financial Officer has left the company On the 1st of February, Carit Andersen's tenure as Chief Financial Officer ended after 2.0 years in the role. As of September 2020, Carit personally held only 11.72k shares (kr196k worth at the time). A total of 2 executives have left over the last 12 months. Is New 90 Day High Low • Jan 06
New 90-day high: kr17.65 The company is up 5.0% from its price of kr16.75 on 08 October 2020. The Swedish market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 16% over the same period. Is New 90 Day High Low • Oct 13
New 90-day low: kr16.25 The company is down 15% from its price of kr19.10 on 15 July 2020. The Swedish market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 20% over the same period. Is New 90 Day High Low • Sep 28
New 90-day low: kr17.30 The company is down 6.0% from its price of kr18.45 on 30 June 2020. The Swedish market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 18% over the same period.